The International Myeloma Foundation (IMF) presents its 2016 Research Grant awards at a ceremony held during the 57th annual meeting of the American Society of Hematology (ASH) in December 2015 at Orlando, FL, USA.
Senior Grant Recipients
Irene Ghobrial, MD (BSRI)
Dana-Farber Cancer Institute
Boston, MA, USA
Blood biomarkers for clonal progression in multiple myeloma
Norma C. Gutierrez, MD, PhD (BSRI)
Salamanca Institute for Biomedical Research (IBSAL)
University Hospital of Salamanca
Salamanca, Spain
Optimization and validation of an automated capillary immunoelectrophoresis technology to quantify the expression of essential proteins in the pathogenesis of multiple myeloma
Yang Yang, MD, PhD
University of Alabama at Birmingham
Birmingham, AL, USA
Runx2 regulation of EMT and a bone resident of cell-like phenotype in myeloma cells
Fenghuang Zhan, MD, PhD
University of Iowa
Iowa City, IA, USA
NEK2 signaling in myeloma osteolytic disease
Junior Grant Recipients
Giada Bianchi, MD
Dana-Farber Cancer Institute
Boston, MA, USA
Investigating the Role of Robo1 in Migration and Homing in Multiple Myeloma
Barbara Castella, PhD
CERMS - AOU Citta della salute e della scienza di Torino
Torino, Italy
Targeting the inhibitory pathways in the bone marrow microenvironment of multiple myeloma patients
Padraig D’Arcy, PhD
Karolinska Institute
Stockholm, Sweden
Proteasome Deubiquitinase Inhibitors as a new treatment for Multiple Myeloma
Geoffrey M. Matthews, PhD
Dana-Farber Cancer Institute
Boston, MA
Treating myeloma through inducing degradation of BET bromodomain proteins
Vijay Ramakrishnan, PhD
Mayo Clinic
Rochester, MN, USA
Targeting glutamine addiction in MM cells to inhibit disease progression and enhance myeloma therapeutics
IMF Japan Aki Horinouchi Research Grant
Yoshiaki Chinen MD, PhD
Kyoto Prefectural University of Medicine
Graduate School of Medical Science
Kyoto, Japan
Regulation of PDPK1 and its clinical significance in multiple myeloma
Daiju Ichikawa, PhD
Keio University
Kyoto, Japan
Identification of novel thalidomide-binding proteins and drug design for teratogenicity-negative IMiDs

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.